Patent application number | Description | Published |
20080248456 | Reorientable Dry Erase Board - This invention relates generally to boards for writing or display, and more particularly to reusable, double sided, reorientable, portable and reconfigurable boards that permit writing to be easily removed. In one embodiment, a writing board comprises a frame, a front panel and a rear panel mounted in the frame, wherein the front panel comprises a first writing surface and the rear panel comprises a second writing surface opposite the first writing surface, wherein the first writing surface and the second writing surface are each adapted to erasably receive writing thereon. The writing board is reorientable to receive erasable writing on the first writing surface and the second writing surface. | 10-09-2008 |
20080286744 | Foldable Dry Erase Board - This invention relates generally to writing boards, and more particularly to reusable and foldable boards that permit writing to be easily removed. In one embodiment, a writing board comprises a substrate comprising a front panel, a rear panel opposite the front panel, and a plurality of spaced apart ribs connecting the front panel to the rear panel, wherein the front panel and the rear panel are integrally formed with the plurality of ribs. The writing board of this embodiment further includes at least one backslit formed in the rear panel, at least one living hinge formed in the front panel opposite the at least one backslit to form at least one outer panel, and at least one holding mechanism coupled to the at least one outer panel to maintain the outer panel in one of a substantially open, unfolded position or a substantially closed, folded position. | 11-20-2008 |
Patent application number | Description | Published |
20120195924 | ADENOVIRAL VECTOR VACCINE - Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term. | 08-02-2012 |
20120276148 | ADENOVIRAL VECTOR VACCINE - Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term. | 11-01-2012 |
20130149330 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF BLOCKING BACILLUS ANTHRACIS - The present invention is directed to novel pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of multiple strains of | 06-13-2013 |
20140080208 | ADENOVIRAL VECTOR VACCINE - Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term. | 03-20-2014 |
20140127252 | TULAREMIA-TAA/CD40L VACCINE - A Tularemia vaccine proposes to induce antibodies which through their binding to the target proteins of the vaccine strategy will inactivate the proteins essential to mediating the secretory function of the pilus proteins of the “type IV pilus proteins” or Tfp proteins, thereby impairing the formation of the pilus proteins on the surface of the FT which are needed for binding and entry of the FT into macrophages, and will inhibit the secretion of several factors of FT which are necessary for the virulence of the FT, and which are missing in attenuated strains of FT used in current attenuate strain vaccination strategies. The vaccine may be a mixture of DNA plasmids encoding TAA/ecdCD4OL protein vaccines in which the TAA is comprised of fragments of the following Tularemia proteins: Tfp, pilA, pilC, pilT, and pilQ, | 05-08-2014 |
20150064209 | METHODS FOR GENERATING IMMUNITY TO ANTIGEN - Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein. | 03-05-2015 |